

01 October 2025

DYSPRO PRESCRIBED TO FIRST PATIENTS

- First patient prescriptions of Dyspro™, EVE's proprietary cannabinoid-based gummy for dysmenorrhoea and endometriosis under the TGA's Special Access Scheme and Authorised Prescribers pathways.
- Marks the transition from production and distribution to real-world patient access.
- Launch of Reclaim My Cycle (www.reclaimmycycle.com), a dedicated online hub to support women experiencing dysmenorrhoea and endometriosis.
- Platform provides educational resources for consumers and clinical information for healthcare practitioners.
- Designed to provide educational resources and support in addressing broader unmet needs in women's health.
- Initiative aligns with EVE's strategy to combine digital engagement, practitioner education, and patient support to drive adoption and responsible access.

EVE Health Group Limited (ASX: EVE, EVE or the Company) is pleased to announce that Dyspro™, the Company's proprietary cannabinoid-based gummy for treatment of dysmenorrhoea and endometriosis, has been prescribed to the first patients under the Therapeutic Goods Administration's Special Access Scheme. This milestone follows the successful completion of GMP manufacture and distribution and marks the next step in EVE's commercial rollout.

Prescriber Engagement

EVE is progressing further partnerships to broaden prescribing and distribution channels, with the aim of scaling patient access and supporting future export opportunities. In parallel, additional practitioner education initiatives are in development to strengthen awareness and adoption across clinical networks.

To support clinical adoption, EVE hosted its first in-clinic education seminar last week. The session brought together healthcare practitioners to demonstrate the therapeutic benefits of Dyspro™ and to provide practical prescribing guidance.

Reclaim My Cycle Platform - www.reclaimmycycle.com

As part of the support activities for the launch, the Company has launched *Reclaim My Cycle*, an online community and education platform designed to empower women managing dysmenorrhoea and endometriosis, and to provide healthcare practitioners with up-to-date clinical resources.

By combining patient-friendly education with practitioner-focused materials, Reclaim My Cycle supports both consumer engagement and clinical adoption, creating a bridge between awareness, prescription, and treatment outcomes.

Platform Features

- Consumer resources: plain-language guides on dysmenorrhoea and endometriosis, practical management tips, and pathways to seek medical care.
- Practitioner tools: prescribing information, clinical evidence updates, and continuing education modules.
- Access pathways: direct links to TeleDocs Clinic telehealth network for managing women's health, with further prescribers and distribution partners added as they are onboarded.
- Community focus: sharing stories, breaking down stigma, and encouraging dialogue around menstrual and reproductive health.

EVE Chairman, Rod Hannington, said: The first patient prescriptions of Dyspro™ mark an important milestone in our mission to bring meaningful relief to women living with painful menstrual symptoms. Moving from manufacture and distribution to real-world use demonstrates the impact Dyspro™ can have, and we are proud to support this launch with education and community resources through *Reclaim My Cycle*."

Addressing an Unmet Need

Dysmenorrhoea affects more than 70% of Australian women of reproductive age, with significant impact on daily life, productivity, and wellbeing. In severe cases, symptoms are linked to endometriosis, a chronic condition that affects up to 14% of reproductive-age women. The economic burden in Australia is estimated at AUD \$14.2 billion, largely due to lost productivity.^{1 2}

By launching Reclaim My Cycle, EVE is ensuring that women, families, and clinicians have access to credible, science-led resources at the same time Dyspro™ becomes available on prescription.

Authorised for release by the Board of Directors.

Company enquiries

+61 8 6465 5500

info@evehealthgroup.com.au

About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian life sciences company focused on developing and commercialising innovative pharmaceutical solutions in high-growth therapeutic areas. The company's lead assets include Dyspro, a fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo, an oral dissolving film for erectile dysfunction designed to deliver rapid onset and improved patient convenience. Both products leverage EVE's proprietary formulation and delivery technologies to enhance bioavailability and clinical outcomes, representing near-term commercial opportunities in large, underserved global markets.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.

¹ Mardon A.K. et al. *Problematic Periods Costing Young Women—The Impact of Menstrual Symptoms on Work and Study*. *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 2024. <https://obgyn.onlinelibrary.wiley.com/doi/10.1111/ajo.13926>

² Armour M. et al. *The cost of illness and economic burden of endometriosis and chronic pelvic pain in Australia: A national online survey*. <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0223316>

Figures in Armour et al. (2019) were originally reported in 2017 International dollars (Int \$), using purchasing power parity (PPP) to approximate US dollar values. These are expressed in USD here for clarity.